TY - JOUR
T1 - Clinical approach to pediatric transverse myelitis, neuromyelitis optica spectrum disorder and acute flaccid myelitis
AU - Wang, Cynthia
AU - Greenberg, Benjamin
N1 - Funding Information:
Conflicts of Interest: Greenberg has received grant support from the NIH, PCORI, NMSS, Guthy Jackson Charitable Foundation for NMO, Genentech, Chugai, Medimmune and Medday. He has received consulting fees from Alexion and Novartis. He serves on the advisory board for the Transverse Myelitis Association. Wang’s fellowship was supported by the Transverse Myelitis Association.
Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/5
Y1 - 2019/5
N2 - Pediatric transverse myelitis (TM) is an acquired, immune-mediated disorder that leads to injury of the spinal cord and often manifests as weakness, numbness, bowel dysfunction, and/or bladder dysfunction. Multiple etiologies for myelitis can result in a similar clinical presentation, including idiopathic transverse myelitis (TM), multiple sclerosis (MS), neuromyeltis optica spectrum disorder (NMOSD) associated with anti-aquaporin 4 antibodies, MOG antibody-associated disease, and acute flaccid myelitis (AFM). Diagnosis relies on clinical recognition of the syndrome and confirming inflammation through imaging and/or laboratory studies. Acute treatment is targeted at decreasing immune-mediated injury, and chronic preventative therapy may be indicated if TM is determined to be a manifestation of a relapsing disorder (i.e., NMOSD). Timely recognition and treatment of acute transverse myelitis is essential, as it can be associated with significant morbidity and long-term disability.
AB - Pediatric transverse myelitis (TM) is an acquired, immune-mediated disorder that leads to injury of the spinal cord and often manifests as weakness, numbness, bowel dysfunction, and/or bladder dysfunction. Multiple etiologies for myelitis can result in a similar clinical presentation, including idiopathic transverse myelitis (TM), multiple sclerosis (MS), neuromyeltis optica spectrum disorder (NMOSD) associated with anti-aquaporin 4 antibodies, MOG antibody-associated disease, and acute flaccid myelitis (AFM). Diagnosis relies on clinical recognition of the syndrome and confirming inflammation through imaging and/or laboratory studies. Acute treatment is targeted at decreasing immune-mediated injury, and chronic preventative therapy may be indicated if TM is determined to be a manifestation of a relapsing disorder (i.e., NMOSD). Timely recognition and treatment of acute transverse myelitis is essential, as it can be associated with significant morbidity and long-term disability.
KW - Acute flaccid myelitis
KW - Neuromyelitis optica spectrum order
KW - Pediatric
KW - Review
KW - Transverse myelitis
UR - http://www.scopus.com/inward/record.url?scp=85083212937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083212937&partnerID=8YFLogxK
U2 - 10.3390/children6010070
DO - 10.3390/children6010070
M3 - Review article
AN - SCOPUS:85083212937
SN - 2227-9067
VL - 6
JO - Children
JF - Children
IS - 5
M1 - 70
ER -